AVTR vs. ILMN: Avantor vs. Illumina Stock Comparison
How do Avantor (AVTR) and Illumina (ILMN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Illumina (ILMN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | AVTR | ILMN |
|---|---|---|
| Name | Avantor, Inc. | Illumina Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.48 billion USD | 32.23 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | July 28, 2000 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Total Return (1Y) | 36.41% | 79.70% |
| Total Return (3Y, Annualized) | -5.02% | 28.16% |
| Total Return (5Y, Annualized) | -16.62% | -10.65% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 48.47% |
| Beta (5Y) | 0.94 | 1.46 |
| Max Drawdown (5Y) | -82.42% | -82.95% |
| Avg. Volume (3M) | 8.56M | 2.77M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 1.56 |
| Sortino Ratio (1Y) | 1.17 | 2.25 |
Profitability
ROE (TTM)
Illumina (ILMN) at 32.39% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for ILMN.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.39%
- Max
- 109.18%
- ILMN
- 32.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Illumina (ILMN) at 19.72% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.72%
- ILMN
- 19.72%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Illumina (ILMN) at 20.02% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 83.12%
- ILMN
- 20.02%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| ROE (TTM) | 5.91% | 32.39% |
| ROA (TTM) | 2.83% | 8.32% |
| Net Margin (TTM) | 5.08% | 19.72% |
| Operating Margin (TTM) | 8.19% | 20.02% |
| Gross Margin (TTM) | 31.59% | 67.68% |
Growth
Revenue Growth
Both Avantor (AVTR) at -3.41% and Illumina (ILMN) at -0.66% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.
EPS Growth
Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.
Growth Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | -0.66% |
| Revenue Growth (3Y CAGR) | -4.46% | -1.78% |
| EPS Growth (YoY) | -175.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ILMN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.74
- Max
- 1.42
- ILMN
- 0.74
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 2.63 |
| Debt / Equity (MRQ) | 0.63 | 0.74 |
| Net Debt / EBITDA | 3.40 | 0.85 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Avantor (AVTR) at 30.94 and Illumina (ILMN) at 36.68 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.68
- Max
- 85.34
- Q3
- 43.46
- ILMN
- 36.68
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Illumina (ILMN) at 7.10 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.10
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ILMN
- 7.10
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Avantor (AVTR) at 1.80 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.30
- Max
- 13.53
- ILMN
- 10.30
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | ILMN |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 36.68 |
| P/S Ratio (TTM) | 1.58 | 7.10 |
| P/B Ratio (MRQ) | 1.80 | 10.30 |
| Free Cash Flow Yield (TTM) | 4.21% | 2.67% |